https://www.businesswire.com/news/home/20180730005212/en/

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Jul 30, 2018--Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the presentation of new data showing that the DecisionDx ® -Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging. The study was presented at the DERM2018 NP/PA CME Conference held in Las Vegas, Nevada.

The study assessed the impact on risk assessment for patients with Stage I-III melanoma when including results from the DecisionDx-Melanoma test along with population-based AJCC staging in a 690-patient cohort. The DecisionDx-Melanoma test uses tumor biology to provide an individual risk assessment for patients with melanoma. Results from this analysis showed that the addition of the test result to clinicopathologic AJCC staging significantly improved risk stratification. Technical reliability in over 17,000 clinical test orders was also assessed, and showed 98.3% reporting success for samples with adequate tumor content.